Harrow Inc. (HROW)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harrow: VEVYE And Its Impact On The DED Market
Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber base indicate significant patient benefits and long-term revenue potential, supported by a patent extending to 2039.
Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Will Harrow (HROW) Report Negative Earnings Next Week? What You Should Know
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best Momentum Stocks to Buy for November 6th
HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024.
Harrow (HROW) Upgraded to Strong Buy: What Does It Mean for the Stock?
Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Harrow (HROW) Could Rally 25.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
I Am Banking On The Silver Tsunami With Big Dividends
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Harrow Inc (HROW) Shares Up 3.26% on Oct 2
Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45.
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago.
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
